Literature DB >> 27449771

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.

Xiaohong R Yang1, Melissa Rotunno1,2, Yanzi Xiao1, Christian Ingvar3, Hildur Helgadottir4, Lorenza Pastorino5,6, Remco van Doorn7, Hunter Bennett1, Cole Graham1, Joshua N Sampson1, Michael Malasky1,8, Aurelie Vogt1,8, Bin Zhu1,8, Giovanna Bianchi-Scarra5,6, William Bruno5,6, Paola Queirolo9, Giuseppe Fornarini9, Johan Hansson4, Rainer Tuominen4, Laurie Burdett1,8, Belynda Hicks1,8, Amy Hutchinson1,8, Kristine Jones1,8, Meredith Yeager1,8, Stephen J Chanock1, Maria Teresa Landi1, Veronica Höiom4, Håkan Olsson10, Nelleke Gruis7, Paola Ghiorzo5,6, Margaret A Tucker1, Alisa M Goldstein11,12.   

Abstract

The risk of pancreatic cancer (PC) is increased in melanoma-prone families but the causal relationship between germline CDKN2A mutations and PC risk is uncertain, suggesting the existence of non-CDKN2A factors. One genetic possibility involves patients having mutations in multiple high-risk PC-related genes; however, no systematic examination has yet been conducted. We used next-generation sequencing data to examine 24 putative PC-related genes in 43 PC patients with and 23 PC patients without germline CDKN2A mutations and 1001 controls. For each gene and the four pathways in which they occurred, we tested whether PC patients (overall or CDKN2A+ and CDKN2A- cases separately) had an increased number of rare nonsynonymous variants. Overall, we identified 35 missense variants in PC patients, 14 in CDKN2A+ and 21 in CDKN2A- PC cases. We found nominally significant associations for mismatch repair genes (MLH1, MSH2, MSH6, PMS2) in all PC patients and for ATM, CPA1, and PMS2 in CDKN2A- PC patients. Further, nine CDKN2A+ and four CDKN2A- PC patients had rare potentially deleterious variants in multiple PC-related genes. Loss-of-function variants were only observed in CDKN2A- PC patients, with ATM having the most pathogenic variants. Also, ATM variants (n = 5) were only observed in CDKN2A- PC patients with a family history that included digestive system tumors. Our results suggest that a subset of PC patients may have increased risk because of germline mutations in multiple PC-related genes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27449771      PMCID: PMC5152573          DOI: 10.1007/s00439-016-1715-1

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  29 in total

1.  dbSNP: the NCBI database of genetic variation.

Authors:  S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.

Authors:  Chengliang Dong; Peng Wei; Xueqiu Jian; Richard Gibbs; Eric Boerwinkle; Kai Wang; Xiaoming Liu
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

3.  Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.

Authors:  P Ghiorzo; V Pensotti; G Fornarini; S Sciallero; L Battistuzzi; F Belli; L Bonelli; G Borgonovo; W Bruno; A Gozza; S Gargiulo; L Mastracci; S Nasti; G Palmieri; F Papadia; L Pastorino; A Russo; V Savarino; L Varesco; L Bernard; G Bianchi Scarrà
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

4.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

5.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).

Authors:  H F Vasen; N A Gruis; R R Frants; P A van Der Velden; E T Hille; W Bergman
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

6.  High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Authors:  A Borg; T Sandberg; K Nilsson; O Johannsson; M Klinker; A Måsbäck; J Westerdahl; H Olsson; C Ingvar
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

7.  INK4/ARF germline alterations in pancreatic cancer patients.

Authors:  P Ghiorzo; L Pastorino; L Bonelli; R Cusano; A Nicora; S Zupo; P Queirolo; M Sertoli; V Pugliese; G Bianchi-Scarrà
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

Review 8.  The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine.

Authors:  Peter D Stenson; Matthew Mort; Edward V Ball; Katy Shaw; Andrew Phillips; David N Cooper
Journal:  Hum Genet       Date:  2014-01       Impact factor: 4.132

9.  Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.

Authors:  Femke A de Snoo; D Timothy Bishop; Wilma Bergman; Inge van Leeuwen; Clasine van der Drift; Frans A van Nieuwpoort; Coby J Out-Luiting; Hans F Vasen; Jeanet A C ter Huurne; Rune R Frants; Rein Willemze; Martijn H Breuning; Nelleke A Gruis
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

10.  High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.

Authors:  Hildur Helgadottir; Veronica Höiom; Göran Jönsson; Rainer Tuominen; Christian Ingvar; Ake Borg; Håkan Olsson; Johan Hansson
Journal:  J Med Genet       Date:  2014-06-16       Impact factor: 6.318

View more
  16 in total

1.  Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades.

Authors:  Margaret A Tucker; David E Elder; Michael Curry; Mary C Fraser; Virginia Pichler; Deborah Zametkin; Xiaohong R Yang; Alisa M Goldstein
Journal:  J Invest Dermatol       Date:  2018-02-08       Impact factor: 8.551

2.  Rare germline variants in known melanoma susceptibility genes in familial melanoma.

Authors:  Alisa M Goldstein; Yanzi Xiao; Joshua Sampson; Bin Zhu; Melissa Rotunno; Hunter Bennett; Yixuan Wen; Kristine Jones; Aurelie Vogt; Laurie Burdette; Wen Luo; Bin Zhu; Meredith Yeager; Belynda Hicks; Jiali Han; Immaculata De Vivo; Stella Koutros; Gabriella Andreotti; Laura Beane-Freeman; Mark Purdue; Neal D Freedman; Stephen J Chanock; Margaret A Tucker; Xiaohong R Yang
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

Review 3.  Progress report: familial pancreatic cancer.

Authors:  Ioannis Mintziras; Detlef K Bartsch
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

4.  Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts.

Authors:  Wei Zhan; Celeste A Shelton; Phil J Greer; Randall E Brand; David C Whitcomb
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

5.  Rare germline deleterious variants increase susceptibility for lung cancer.

Authors:  Jian Sang; Tongwu Zhang; Jung Kim; Mengying Li; Angela C Pesatori; Dario Consonni; Lei Song; Jia Liu; Wei Zhao; Phuc H Hoang; Dave S Campbell; James Feng; Monica E D'Arcy; Naoise Synnott; Yingxi Chen; Zeni Wu; Bin Zhu; Xiaohong R Yang; Kevin M Brown; Jiyeon Choi; Jianxin Shi; Maria Teresa Landi
Journal:  Hum Mol Genet       Date:  2022-10-10       Impact factor: 5.121

6.  Integrated Analysis of Coexpression and Exome Sequencing to Prioritize Susceptibility Genes for Familial Cutaneous Melanoma.

Authors:  Sally Yepes; Margaret A Tucker; Hela Koka; Yanzi Xiao; Tongwu Zhang; Kristine Jones; Aurelie Vogt; Laurie Burdette; Wen Luo; Bin Zhu; Amy Hutchinson; Meredith Yeager; Belynda Hicks; Kevin M Brown; Neal D Freedman; Stephen J Chanock; Alisa M Goldstein; Xiaohong R Yang
Journal:  J Invest Dermatol       Date:  2022-02-16       Impact factor: 7.590

Review 7.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

8.  Familial pancreatic cancer: who should be considered for genetic testing?

Authors:  Kinyas Kartal; Zoe Guan; Rong Tang; Molly Griffin; Yan Wang; Danielle Braun; Alison P Klein; Kevin S Hughes
Journal:  Ir J Med Sci       Date:  2021-03-17       Impact factor: 1.568

9.  Identification, genetic testing, and management of hereditary melanoma.

Authors:  Sancy A Leachman; Olivia M Lucero; Jone E Sampson; Pamela Cassidy; William Bruno; Paola Queirolo; Paola Ghiorzo
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

10.  Functional analysis of a CDKN2A 5'UTR germline variant associated with pancreatic cancer development.

Authors:  William Bruno; Virginia Andreotti; Alessandra Bisio; Lorenza Pastorino; Giuseppe Fornarini; Stefania Sciallero; Giovanna Bianchi-Scarrà; Alberto Inga; Paola Ghiorzo
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.